brequinar has been researched along with Genital Neoplasms, Female in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Armand, JP; Barbu, M; Carde, P; Chabot, GG; de Forni, M; Domenge, C; Fontana, X; Gouyette, A; Recondo, G | 1 |
| Bork, E; Hansen, HH; Vest, S | 1 |
1 trial(s) available for brequinar and Genital Neoplasms, Female
| Article | Year |
|---|---|
Phase I and pharmacokinetic study of brequinar (DUP 785; NSC 368390) in cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Biphenyl Compounds; Dose-Response Relationship, Drug; Female; Genital Neoplasms, Female; Half-Life; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Thrombocytopenia | 1993 |
1 other study(ies) available for brequinar and Genital Neoplasms, Female
| Article | Year |
|---|---|
A phase I clinical and pharmacokinetic study of Brequinar sodium, DUP 785 (NSC 368390), using a weekly and a biweekly schedule.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Biphenyl Compounds; Drug Administration Schedule; Drug Evaluation; Female; Genital Neoplasms, Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Platelet Count; Urologic Neoplasms | 1989 |